Epidermis

Sofwave Gains Approval to Market the SUPERB™ Non-Invasive Wrinkle Reduction Device in Brazil

Retrieved on: 
Wednesday, November 2, 2022
Marketing, American Academy, Growth, Epidermis, 3D, Transducer, Lifting, US Foods, Dermatology, GLOBE, Time, Technology, Physician, ANVISA, Heat, Government, TASE, Chin, Company, FDA, Patient, Food, International Society, Plastic, Solution, Medical imaging

SAN CLEMENTE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Brazil’s health regulatory agency, ANVISA, the equivalent of the US Food and Drug Administration, has given an approval to market Sofwave’s™ SUPERB device in Brazil. The approval is required prior to the commercialization and marketing of medical devices in Brazil. Permission to distribute Sofwave’s aesthetic devices is immediate, following public notice of the approval via Brazil’s government newspaper.

Key Points: 
  • The approval is required prior to the commercialization and marketing of medical devices in Brazil.
  • Permission to distribute Sofwaves aesthetic devices is immediate, following public notice of the approval via Brazils government newspaper.
  • Sofwaves state-of-the-art SUPERB(Synchronous Ultrasound Parallel Beam) Technology addresses the growing demand for non-invasive treatments that deliver noticeable wrinkle reduction.
  • Sofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction and lifting using proprietary breakthrough technology.

EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®

Retrieved on: 
Friday, October 21, 2022
Cream, BDP, Epidermis, GLOBE, PAD, Novin, MC2, Diffusion, Therapy, CAL, Cosmetics

In a second poster, diffusion of these active ingredients through human epidermis was investigated in an in vitro Franz diffusion study.

Key Points: 
  • In a second poster, diffusion of these active ingredients through human epidermis was investigated in an in vitro Franz diffusion study.
  • This demonstrated that consistently higher amounts of CAL and BDP diffused through the epidermis with the PAD Technology based cream compared with the CAL/BDP topical suspension.
  • WYNZORA Cream uses PAD Technology, which uniquely enables calcipotriene and betamethasone dipropionate to be combined in a stable, convenient-to-use aqueous formulation.
  • Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases.

Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy

Retrieved on: 
Tuesday, October 18, 2022
Mycosis fungoides, Birth, Caregiver, Skin, Birth control, Smoking, Journal of Investigative Dermatology, Corporation, Blistering, Woman, Blister, Water, Dermis, Epidermis, Environment, Fertility, Fetus, Mycosis, Visual impairment, European Commission, Ulcer, Photophobia, Infertility, Permeation, Inflammation, Chlormethine, Red, Cancer, Medical Affairs Bureau, JAMA Dermatology, IB, Hypersensitivity, Itch, FDA, Dermatology, Female, Risk, Growth, Dermatitis, Research, Respect, Eye injury, Pain, Ageing, Royal commission, Nasal mucosa, Hyperpigmentation, Patient, Burns, Anaphylaxis, T-cell lymphoma, Swelling, CL, Toxicity, Adult, Safety, Heart, Pharmaceutical industry, Medical device, Medical imaging, Vaccine, Dentistry, EU

This article, Chlormethine Gel for the treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing, evaluated part of the mode of action of chlormethine (CL) gel once applied to the skin.

Key Points: 
  • This article, Chlormethine Gel for the treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing, evaluated part of the mode of action of chlormethine (CL) gel once applied to the skin.
  • In a preliminary, proof-of-concept, in vitro study, the release profile of 0.016% chlormethine gel was evaluated compared to an ointment-based formulation of CL.
  • Title: Chlormethine Gel for the treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing.
  • Understanding CL gels mode of action and how it permeates through the skin is extremely important for its use in clinical practice.

Aesthetics Biomedical ® Inc. Announces FDA Clearance of Vivace Ultra™, The First-and-Only Personalized Radiofrequency (RF) Microneedling Technology

Retrieved on: 
Wednesday, October 19, 2022
Well, Physician, Dermatology, Female, Patient, HIPAA, Research, Technology, Electrocoagulation, Trial of the century, Marketing, MD, RF, Hemostasis, CEO, Dermis, Skin, Epidermis, FDA, Calibration, Lists of people executed in the United States, Male, Medical device, Medical imaging, RealSelf

PHOENIX, Oct. 19, 2022 /PRNewswire-PRWeb/ -- Today marks the beginning of (another) new era for Aesthetics Biomedical® Inc. Well-known for leading advancements in aesthetics technology, Aesthetics Biomedical's brand is committed to creation, distribution and marketing of novel aesthetic devices, products and services. Vivace Ultra™, the next generation and future of personalized aesthetics, has cleared the United States Food and Drug Administration (FDA) intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.

Key Points: 
  • Well-known for leading advancements in aesthetics technology, Aesthetics Biomedical's brand is committed to creation, distribution and marketing of novel aesthetic devices, products and services.
  • Vivace Ultra, the next generation and future of personalized aesthetics, has cleared the United States Food and Drug Administration (FDA) intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.
  • In addition, this technology offers four unique delay speeds for optimal time pulses as well as the ability to toggle radiofrequency on or off.
  • About Aesthetics Biomedical Inc.: Headquartered in Phoenix, AZ., Aesthetics Biomedical is committed to the development and distribution of novel aesthetic devices, products and services in the global market.

DermTech Presents on Translational Medicine to Revolutionize Dermatologic Care at the Biomarkers & Precision Medicine USA Congress

Retrieved on: 
Monday, October 10, 2022
Software, Research, Managed Care, General Health, Oncology, Medical Devices, Technology, Genetics, Health Technology, Science, Other Technology, Health, Adoption, Congress, Data collection, Psoriasis, U.S. Securities and Exchange Commission, Disease, Medicine, SEC, Efficiency, Specialization, Dermatology, Genomics, Annual report, NASDAQ, Patient, Research, Security (finance), Â, Collection, Inflammation, Technology, Precision medicine, Private Securities Litigation Reform Act, Cedars-Sinai Medical Center, Medicare, Atopic dermatitis, Skin, Lupus, Epidermis, AD, Clinical trial, Biomarker, Pathology, Solution, Smart, Medical imaging

DermTech , Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced its presentation at the Biomarkers & Precision Medicine USA Congress, held from Oct. 3-4 in San Diego.

Key Points: 
  • DermTech , Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced its presentation at the Biomarkers & Precision Medicine USA Congress, held from Oct. 3-4 in San Diego.
  • Erica Montano, Ph.D., a DermTech Stratum research scientist, presented on the translational medicine services of DermTech Stratum and its precision-based approach to dermatology.
  • The presentation, titled Translational Research to Revolutionize Dermatologic Care, emphasized the Companys proprietary Smart Sticker and platform technology, highlighting its capabilities, specializations and advantages.
  • I am pleased for the opportunity to present on behalf of DermTech Stratum at the 6th Annual Biomarkers & Precision Medicine USA Congress, sharing our translational medicine services that may revolutionize dermatologic care and research and development through precision and personalization, said Dr. Montano.

Black Armor Tattoo Uses the Astanza Duality Laser to Fade and Transform Cover-Up Tattoos in Murrysville, PA

Retrieved on: 
Monday, September 26, 2022
YouTube, Duality, Hair removal, Time, Armour, Laser, Twitter, Tattoo, Epidermis, LinkedIn, Life, Dermis, Partnership, Ink, Instagram, Support, Music, GLOBE, Marketing, Color, Mineral oil, Facebook

Murrysville, Pennsylvania, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Black Armor Tattoo , a leading tattoo shop in Murrysville, PA, added the Astanza Duality laser to revise, modify, and remove existing tattoos and unwanted ink.

Key Points: 
  • Murrysville, Pennsylvania, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Black Armor Tattoo , a leading tattoo shop in Murrysville, PA, added the Astanza Duality laser to revise, modify, and remove existing tattoos and unwanted ink.
  • Unlike other laser tattoo removal providers that focus on erasing regretful tattoos, Black Armor Tattoo uses the laser as a reparative tool to fade tattoos and improve cover-up art.
  • Offering a fully capable laser tattoo removal system in-house will only add to Black Armor Tattoos already established client base.
  • Black Armor Tattoo offers free consultations for laser tattoo removal and tattoo assessments.

Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa

Retrieved on: 
Wednesday, September 21, 2022
Priority, Tears, Fibrosis, Twitter, Risk, PRV, FDA, Food, Finger, VII, European Medicines Agency, The, Epidermis, LinkedIn, Company, Population, Suma, Dermis, Degenerative disease, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trauma, Securities and Exchange Commission (Philippines), COL7, PIP, Blister, DEB, MAA, Tissue, Private Securities Litigation Reform Act, Skin, NASDAQ, Squamous cell carcinoma, Lung, KRYS, Priority review, GLOBE, Marketing, EMA, Research and development, COL7A1, Pharmaceutical industry, EU

PITTSBURGH, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has adopted a positive opinion on the Pediatric Investigation Plan (PIP) for beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa.

Key Points: 
  • PITTSBURGH, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has adopted a positive opinion on the Pediatric Investigation Plan (PIP) for beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa.
  • The positive opinion is based on the B-VEC non-clinical safety program as well as data from the clinical studies conducted in the US that will be included in the upcoming MAA.
  • The U.S. Food and Drug Administration (FDA) and EMA have each granted B-VEC orphan drug designation for the treatment of DEB.
  • The FDA has granted B-VEC fast track designation, Regenerative Medicine Advanced Therapy (RMAT) and rare pediatric disease designation for the treatment of DEB.

Investor Webinar Briefing (RCEL, AVH)

Retrieved on: 
Monday, September 19, 2022
Burn, ASX, Contraindication, CFO, Safety, Q&A, FDA, Food, Epidermis, PDT, USE, Autotransplantation, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Burns, CEO, Technology, Goal, Solution, RES, NASDAQ, Health care, Skin, Avita Medical, AEST, AVH, Regenerative medicine, Medical device

To register for the presentation, please follow this Zoom link: https://us02web.zoom.us/webinar/register/WN_ZTCqHqzbQrqxhDQwyjHXKQ

Key Points: 
  • To register for the presentation, please follow this Zoom link: https://us02web.zoom.us/webinar/register/WN_ZTCqHqzbQrqxhDQwyjHXKQ
    Participants are invited to submit questions via the registration page or during the webinar via the chat function.
  • A replay will be available on the AVITA Medical website, www.avitamedical.com , following the presentation.
  • AVITA Medical's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin.
  • AVITA Medical's first U.S. product, the RECELL(R) System , was approved by the U.S. Food and Drug Administration (FDA) in September 2018.

Natralus Empowers a More Natural Approach to Skin Health

Retrieved on: 
Tuesday, September 13, 2022
Health, Element, Woman, Chemical substance, Lip, Epidermis, Skin, Habit, Philosophy, Natural Ingredients, CEO, Aloe vera, Irritation, Red, Mayo Clinic, Parent, Pomegranate, Cosmetics

FORT LAUDERDALE, Fla., Sept. 13, 2022 /PRNewswire/ -- Skincare is often seen as a superficial, cosmetic activity. However, it's important for individuals to consider the health of their skin just as much (if not more) than its appearance. Mayo Clinic points out that there are many ways to preserve healthy skin through adjusting everyday habits and activities. Less bathing or showering, shaving carefully, lubricating a razor well, and patting dry with a towel are all recommended — and with good reason, too. Hot water, harsh razors, and abrasive drying can strip oil from the skin. When this happens too often or too aggressively, it can leave the epidermis struggling to stay hydrated and produce enough oil.

Key Points: 
  • Natralus Uses Natural Ingredients and Innovative Formulas for Better Results and Healthier Skin.
  • The Australian natural skin health brand was created with a focus on empowering people to opt for a more natural approach to skincare and wellness.
  • Other Natralus products use unique formulations that include pomegranate, goji berries, aloe vera, elderberry, and many other natural ingredients, each with its own potent effects on skin health.
  • Natural skin health brand Natralus Australia was established in 2010 and operates out of Adelaide, Australia.

Stirling CBD Expands Its Industry-Leading Lotion Lineup

Retrieved on: 
Thursday, September 1, 2022
Inflammation, Magnesium, Osteoarthritis, Research, Menthol, Dead Sea, Helianthus, Balm, Tissue, Myalgia, Skin, Eucalyptus, PTS, Cell, Athlete, GLOBE, Joint, THC production by yeast, Leaf, Arnica, Nutritionist, Aloe vera, Epidermis, Massage, Cosmetics, Aroma compound, CBD, Cannabidiol, Delta

CARY, N.C., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Stirling CBD announces the release of its new maximum strength CBD Magnesium Balm to its CBD lotion lineup.With 2000mg of CBD per 4oz jar, it is the most potent CBD balm available.

Key Points: 
  • CARY, N.C., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Stirling CBD announces the release of its new maximum strength CBD Magnesium Balm to its CBD lotion lineup.With 2000mg of CBD per 4oz jar, it is the most potent CBD balm available.
  • All Stirling CBD Lotions have an incredible 2000mg of CBD in each bottle.
  • Menthol CBD Lotion -This lotion has the maximum amount of CBD and menthol to relieve sore muscles and joints.
  • In addition, Stirling launched its Professional Brand - Stirling Professional CBD - which is sold exclusively to Chiropractors, Gyms, CrossFit Boxes, PTs, and Massage Therapists.